The issue of compulsory licenses for patent rights to pharmaceuticals is becoming more and more controversial in Russia, due to the growing number of important court rulings involving compulsory licenses affecting leaders of the pharma industry over the last few years.
Starting in March 2020, Rospatent implemented Covid-19 pandemic containment measures in line with the high-alert regime adopted by the authorities. In particular, new rules were established for handling communication with applicants during the obligatory self-isolation period, such as a ban on accepting paper-based applications and other measures restricting direct communication.
In The Corner Office feature of CEE Legal Matters we ask Managing Partners at leading law firms across Central and Eastern Europe about their unique roles and responsibilities. In light of current events, the question for this online occurrence of the feature is: "What have been the top three most often asked COVID-19 related questions that you have gotten from clients in the last month?”